Unité de Fabrication des Médicaments Valuation
Is UMED undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of UMED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: UMED (TND7.24) is trading above our estimate of fair value (TND4.03)
Significantly Below Fair Value: UMED is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UMED?
Other financial metrics that can be useful for relative valuation.
What is UMED's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | د.ت231.68m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.4x |
Enterprise Value/EBITDA | 8.9x |
PEG Ratio | 1.4x |
Price to Earnings Ratio vs Peers
How does UMED's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 16.8x | ||
A106190 High Tech Pharm | 14.2x | n/a | ₩114.3b |
RX BioSyent | 15.3x | n/a | CA$98.8m |
YSPSAH Y.S.P. Southeast Asia Holding Berhad | 9.4x | n/a | RM350.4m |
A072020 Choong Ang Vaccine Laboratory | 28.5x | n/a | ₩103.9b |
UMED Unité de Fabrication des Médicaments | 17.7x | 12.8% | د.ت231.7m |
Price-To-Earnings vs Peers: UMED is expensive based on its Price-To-Earnings Ratio (17.7x) compared to the peer average (16.8x).
Price to Earnings Ratio vs Industry
How does UMED's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?
Price-To-Earnings vs Industry: UMED is good value based on its Price-To-Earnings Ratio (17.7x) compared to the Global Pharmaceuticals industry average (24.2x).
Price to Earnings Ratio vs Fair Ratio
What is UMED's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 17.7x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate UMED's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.